UK centre for asbestos-related medtech R&D "progressing rapidly"
This article was originally published in Clinica
Executive Summary
The establishment in the UK of a National Centre for Asbestos-Related Diseases (NCARD) is "moving forward" and "progressing quite rapidly", MPs have been told. The issue was on the agenda of yesterday evening's meeting of the Asbestos Sub-Committee of the All-Party Parliamentary Group on Occupational Safety and Health. Chairman Michael Clapham MP told the committee that a leading UK consultant acting as adviser to the committee had held a number of meetings on the project and "is quite satisfied with the progress being made".
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.